Clinical trial · Observational
Experiences With HDR-brachytherapy in Norway
Norwegian Experiences With Interstitial Radiation Treatment (Brachytherapy) for Men With High-risk Localised Prostate Cancer
NCT03162523CI-TRIAL-00027805completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There are 3 articles that will be written about the experience with HDR-brachytherapy (HDR-BT) in patients with high-risk prostate cancer in Norway as part of a doctorial thesis-project. The project will focus on survival, side-effects and dosimetry variables as the main points of interest.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High-Dose Rate Brachytherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Scandinavian Prostate Cancer Group (SPCG), study number 7
- description
- Patients included in hallmark study of SPCG-7 receiving EBRT to 70 Gy in combination with lifelong anti-androgen treatment
- interventionNames
- Radiation: High-Dose Rate Brachytherapy
- label
- Norwegian Urologic Cancer Group (NUCG) study number 7
- description
- Patients receiving EBRT to 74 Gy in combination with hormonal therapy. Approved by ethical comittee. Questionnaires already been completed during a different study (NUCG-7). These patients will therefore not be contacted again.
- interventionNames
- Radiation: High-Dose Rate Brachytherapy
Primary outcomes (3)
- measure
- Overall- and Prostate-Cancer specific mortality in patients treated with HDR-BT compared to EBRT alone
- timeFrame
- 24 weeks
Eligibility
Eligibility (as posted)
- Sex
- Male
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * age, high-risk prostate cancer, general good Health, anatomical favourable condition for brachytherapy Exclusion Criteria: * poor Health, metastasis, T3b stage tumour, Prostate Specific Antigen (PSA) Levels \> 75, biological age \> 75 years
References
Publications (0)
Data not yet available
No reference posted for this study.